Erschienen in:
01.10.2010 | Translational Research and Biomarkers
Clinical Significance of Stanniocalcin 2 as a Prognostic Marker in Gastric Cancer
verfasst von:
Takehiko Yokobori, MD, Koshi Mimori, MD, Hideshi Ishii, MD, Masaaki Iwatsuki, MD, Fumiaki Tanaka, MD, Yukio Kamohara, MD, Keisuke Ieta, MD, Yoshiaki Kita, MD, Yuichiro Doki, MD, Hiroyuki Kuwano, MD, Masaki Mori, MD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 10/2010
Einloggen, um Zugang zu erhalten
Abstract
Background
Stanniocalcins are glycoprotein hormones that were originally found in the endocrine gland of bony fish. Microarray expression data from 32 paired samples of gastric cancer and normal mucosa in a public microarray database showed that the expression level of Stanniocalcin 2 was higher in gastric cancer than in normal gastric mucosa. The clinical significance of Stanniocalcin 2 expression has been observed for several cancers. However, the relationship between Stanniocalcin 2 and clinicopathological factors in gastric cancer has not yet been investigated.
Materials and Methods
We examined the clinical significance of Stanniocalcin 2 in gastric cancer in 108 gastric cancer samples using real-time reverse transcription-polymerase chain reaction (RT–PCR). Immunohistochemical studies were conducted with paraffin sections. The suppression analysis of Stanniocalcin 2 using siRNA was done to determine Stanniocalcin 2’s biological roles.
Results
The level of Stanniocalcin 2 in cancer tissues was higher than in normal tissues (P = .0002). The high Stanniocalcin 2 expression group (n = 54) had more progressive lymph node metastasis (P = .07) and venous invasion (P = .028) than the low-expression group (n = 54). High Stanniocalcin 2 expression was an independent prognostic factor in gastric cancer patients (P = .02). Moreover, siRNA suppression of Stanniocalcin 2 in a gastric cancer cell line inhibited cellular proliferation (P < .05).
Conclusions
The high expression level of Stanniocalcin 2 in gastric cancer tissues could be a very powerful marker of poor prognosis. Therefore, Stanniocalcin 2 is a promising candidate for a molecular target for the treatment of gastric cancer.